AlphAIAlphAI — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Biotechnology

$CING

Cingulate Inc.

Cingulate is a biopharmaceutical company developing medicines with its Precision Timed Release drug delivery platform, which uses an erosion barrier layer to release medication at set intervals in a tablet designed for once-daily, multi-dose administration. Its initial focus is ADHD and anxiety. The pipeline includes CTx-1301, a dexmethylphenidate candidate for ADHD submitted to the FDA for review; CTx-1302, a dextroamphetamine ADHD candidate; and CTx-2103, a buspirone candidate for anxiety. The ADHD candidates are intended for children, adolescents and adults. Cingulate’s business centers on developing and commercializing its drug candidates and platform. It has agreements with Indegene and IQVIA for U.S. commercialization services for CTx-1301, subject to FDA approval, and uses a contract manufacturer for that candidate. The company also evaluates additional product candidates and potential licensing of its platform and products. Cingulate is headquartered in Kansas City, Kansas.

Price · $CINGvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $CING in the last 7 days.

Insider · 30dAll trades →

No SEC Form 4 filings for $CING in the last 30 days.

See all $CING insider activity →
Top stories · $CINGMore →
·SEC EDGAR 8-KLow

Cingulate Inc. (CING): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Cingulate Inc. (CING) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On September 30, 2026, Cingulate Therapeutics LLC (“CTx”), a wholly owned subsidiary of Cingulate Inc. (the “Company”), ent

·stocktwits.com

Why Is CING Stock Jumping Over 4% In Overnight Trading?

Cingulate Inc. (CING) shares rose more than 4% in overnight trading after the USPTO allowed a patent application for a “Trimodal, Precision-Timed Pulsatile Release Tablet” tied to its ADHD drug platform. CING said the allowed status follows a filing in Nov 2023 and comes ahead of an FDA decision on CTx-1301, with a May 31 PDUFA target date.

·tradingview.com

Cingulate Inc. Q2 2026: Revenue $0 Net loss $5.87M — 10-Q Summary

Cingulate Inc. (CING) filed its Q2 2026 10-Q. It reported $0 product revenue and a net loss of $5.87M for the three months ended June 30, 2026, versus a $4.98M net loss in the prior-year quarter. The company said it received an FDA complete response letter for CTx-1301 requesting additional CMC data and outlined CMC and launch preparation plans.

CING sentiment & insider activity

Recent CING coverage spans corporate actions, regulation and market movers.

What's driving CING

  • The amendment is a routine corporate governance update with no material financial impact.

    SEC EDGAR 8-K · Oct 2, 2026

  • USPTO allowance adds IP validation for CTx-1301 delivery technology ahead of the FDA PDUFA decision window.

    stocktwits.com · Aug 15, 2026

  • FDA CMC-focused CRL increases regulatory timeline risk for CTx-1301, while cash runway and manufacturing/CMC work aim to mitigate delays.

    tradingview.com · Aug 13, 2026

  • The filing is a near-term catalyst for CTx-1301 regulatory timing and runway, with additional commercialization contracts that can de-risk launch execution if approval follows.

    SEC EDGAR 8-K · Aug 13, 2026

  • Board action removes a C-suite legal function and signals a potential shift in governance, compliance, or legal resourcing.

    SEC EDGAR 8-K · Jul 23, 2026

AlphAI scores every news story that mentions CING with an AI model for sentiment and relevance, and aggregates insider trades from Cingulate Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CING

Score
$CINGLowSEC EDGAR 8-K

Cingulate Inc. (CING): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Cingulate Inc. (CING) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On September 30, 2026, Cingulate Therapeutics LLC (“CTx”), a wholly owned subsidiary of Cingulate Inc. (the “Company”), ent

$CINGMedstocktwits.com

Why Is CING Stock Jumping Over 4% In Overnight Trading?

Cingulate Inc. (CING) shares rose more than 4% in overnight trading after the USPTO allowed a patent application for a “Trimodal, Precision-Timed Pulsatile Release Tablet” tied to its ADHD drug platform. CING said the allowed status follows a filing in Nov 2023 and comes ahead of an FDA decision on CTx-1301, with a May 31 PDUFA target date.

$CINGMedtradingview.com

Cingulate Inc. Q2 2026: Revenue $0 Net loss $5.87M — 10-Q Summary

Cingulate Inc. (CING) filed its Q2 2026 10-Q. It reported $0 product revenue and a net loss of $5.87M for the three months ended June 30, 2026, versus a $4.98M net loss in the prior-year quarter. The company said it received an FDA complete response letter for CTx-1301 requesting additional CMC data and outlined CMC and launch preparation plans.

$CINGMedSEC EDGAR 8-K

Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Cingulate Inc. (CING) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness Cash and Cash Equivalents of $28.4 Million as of June 30, 2026 Providing Runway Through Mid-2027; Company Advan

$CINGLowSEC EDGAR 8-K

Cingulate Inc. (CING): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Cingulate Inc. (CING) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001862150 0001862150 2026-07-17 2026-07-17 0001862150 CING:CommonStockParValue0.0001PerShareMember 2026-07-17 2026-07-17 0001862150 CING:WarrantsExercisableForCommonStockMember 2026-07-17 2026-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES

$CINGLowSEC EDGAR 8-K

Cingulate Inc. (CING): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Cingulate Inc. (CING) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001862150 0001862150 2026-07-09 2026-07-09 0001862150 CING:CommonStockParValue0.0001PerShareMember 2026-07-09 2026-07-09 0001862150 CING:WarrantsExercisableForCommonStockMember 2026-07-09 2026-07-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES

$CINGLowSEC EDGAR 8-K

Cingulate Inc. (CING): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Cingulate Inc. (CING) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001862150 0001862150 2026-06-30 2026-06-30 0001862150 CING:CommonStockParValue0.0001PerShareMember 2026-06-30 2026-06-30 0001862150 CING:WarrantsExercisableForCommonStockMember 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES

$BJDXMedAI 9/10finanzen.ch

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

Healthcare stocks rose Tuesday on multiple biotech updates. Bluejay Diagnostics (BJDX) surged 100% after a strategic partnership with Argonaut to advance its Symphony diagnostic platform and announced a private placement up to $23.6M. Picard Medical (PMI) gained 60.33% after completing animal implant studies of its Emperor total artificial heart. Legend Biotech (LEGN) rose 42.22% ahead of EHA Phase 1 data. CUE climbed 18.93% with board changes. Cingulate (CING) rose 11.94% despite the FDA declin

$BJDXMedAI 9/10rttnews.com

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

Healthcare biotech gainers on Tuesday included Bluejay Diagnostics (BJDX), which said it signed a strategic partnership with Argonaut to support its Symphony near-patient diagnostic platform; BJDX shares rose 100% to $4.34 and the company also announced a private placement up to $23.6M. Picard Medical (PMI) reported completed animal implant studies for its next-gen Emperor total artificial heart; shares rose 60.33% to $0.27. Legend Biotech (LEGN) said it will present Phase 1 data for LB2501 show

Related tickers

More in Biotechnology